Company · founded 2001
Integral Molecular (United States)
Philadelphia, United States · integralmolecular.com
- Citations, last 5 years
- 597
- Works, last 5 years
- 55
- h-index
- 91
- Scientists listed
- 14
- Grants since 2016
- 36
Grants received
2025–2028 · contract · N44
ANTIBODY REAGENTS FOR IMMUNOLOGIC ANALYSIS OF UNDER-REPRESENTED MAMMALIAN MODELS
Ross Chambers · Integral Molecular (United States) · funded by National Institutes of Health
2025–2030 · cooperative agreement · U24
Generation of Pan-reactive Antibody and Cytokine Reagents for Immunologic Analysis of Bats
Ross S Chambers · Integral Molecular (United States) · funded by National Institutes of Health
2024–2026 · research · R43
Development of Safe and Rapid Reporter Viruses for Studying Pathogenic and Pandemic Viruses
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2024–2027 · grant · SB1
Specificity Screening Drug Development Tool for Biotherapeutic Safety
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2024–2026 · research · R43
Development of Safe and Rapid Reporter Viruses for Studying Pathogenic and Pandemic Viruses
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2024–2027 · grant · SB1
Specificity Screening Drug Development Tool for Biotherapeutic Safety
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2023–2025 · contract · N43
Reagents for Immunologic Analysis of Under-represented Mammalian Models
Ross Chambers · Integral Molecular (United States) · funded by National Institutes of Health
2023–2024 · research · R43
High-throughput Discovery of Antibodies against Understudied Membrane Proteins
Ross S Chambers · Integral Molecular (United States) · funded by National Institutes of Health
2023–2028 · research · R44
High-throughput Discovery of Antibodies against Understudied Membrane Proteins using mRNA
Ross S Chambers · Integral Molecular (United States) · funded by National Institutes of Health
2022–2024 · research · R44
Development of Claudin MAbs for Treating Solid Tumors
Joseph Benjamin Rucker · Integral Molecular (United States) · funded by National Institutes of Health
2022–2024 · research · R44
Development of Claudin MAbs for Treating Solid Tumors
Joseph Benjamin Rucker · Integral Molecular (United States) · funded by National Institutes of Health
2022–2024 · contract · N43
ADJUVANT TARGET DISCOVERY FOR VACCINES AND FOR AUTOIMMUNE AND ALLERGIC DISEASES.
Joseph Rucker · Integral Molecular (United States) · funded by National Institutes of Health
2022–2024 · research · R43
Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2022–2024 · research · R44
Development of Claudin MAbs for Treating Solid Tumors
Joseph Benjamin Rucker · Integral Molecular (United States) · funded by National Institutes of Health
2022–2023 · research · R43
Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Development of Nav1.7 Monoclonal Antibodies for Treating Pain
Joseph Benjamin Rucker · Integral Molecular (United States) · funded by National Institutes of Health
2019–2023 · contract · N01
B-Cell Epitope Discovery and Mechanisms of Antibody Protection for ZIKV, MARV, VEEV Envelope Proteins
Benjamin Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2019–2023 · contract · N01
B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION
Ben Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2019–2020 · contract · N01
B-Cell Epitope Discovery and Mechanisms of Antibody Protection for ZIKV, MARV, VEEV Envelope Proteins
Benjamin Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2019–2020 · contract · N01
B-Cell Epitope Discovery and Mechanisms of Antibody Protection for ZIKV, MARV, and VEEV Envelope Proteins
Benjamin Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2019–2020 · contract · N01
B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION
Ben Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2019–2024 · contract · N01
B-Cell Epitope Discovery and Mechanisms of Antibody Protection for ZIKV, MARV, VEEV Envelope Proteins
Benjamin Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2018–2021 · research · R44
Development of CB1 Monoclonal Antibodies for Treating NASH
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Identifying Agonist MAbs against GPCRs
Joseph Benjamin Rucker · Integral Molecular (United States) · funded by National Institutes of Health
2018–2021 · research · R44
Development of CB1 Monoclonal Antibodies for Treating NASH
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2018–2022 · research · R43
Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2018–2019 · research · R44
High-throughput Identification of Membrane Protein MAbs
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Identifying Agonist MAbs against GPCRs
Joseph Benjamin Rucker · Integral Molecular (United States) · funded by National Institutes of Health
2018–2023 · research · R44
Development of CB1 Monoclonal Antibodies for Treating NASH
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2015–2022 · research · R44
Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2015–2022 · research · R44
Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2015–2023 · research · R44
Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array
Benjamin J Doranz · Integral Molecular (United States) · funded by National Institutes of Health
2014–2022 · research · R44
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders
Joseph Benjamin Rucker · Integral Molecular (United States) · funded by National Institutes of Health
2014–2022 · research · R44
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders
Joseph Benjamin Rucker · Integral Molecular (United States) · funded by National Institutes of Health
2014–2024 · research · R44
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders
Joseph Benjamin Rucker · Integral Molecular (United States) · funded by National Institutes of Health